Cancer Immunology Research

Article	Citations
A Sampling of Highlights from the Literature	112
Abstract A022: Therapeutic inhibition of TREX1 elicits type I interferon–mediated antitumor immunity with minimal autoimmune toxicity	106
Abstract A018: Targeting PTPN1/PTPN2 with KQ-791 enhances NK cell cytotoxicity during tumor rechallenge	94
Abstract B002: Meta-Analysis of Neoantigens: Insights from the Cancer Epitope Database and Analysis Resource (CEDAR)	87
Abstract PR-10: Leveraging peripheral leukocyte recruitment to improve efficacy and mitigate toxicities following checkpoint blockade	76
Host Interactions with Engineered T-cell Micropharmacies	75
Exercise as an Immune Boost: Mechanism-Driven Support for Lifestyle Interventions	74
Correction: Inflammation Mediated by Gut Microbiome Promotes Immune Suppression and Lung Adenocarcinoma Progression	64
Self-Renewing CD8+ T-cell Abundance in Blood Associates with Response to Immunotherapy	63
Abstract LB-C008: Replication stress coupled to cGAS–STING activation defines an innate immune–inflamed transcriptional state in head and neck squamous cell carcinoma that Is enriched for HPV-positive	60
Abstract LB-C012: Immune-Like Circulating Tumor Cells and Large Extracellular Vesicles in Metastatic Breast Cancer	57
Abstract LB-A013: Tuning TCR immunotherapy targeting prostatic acid phosphatase via catch bond modifications for advanced prostate cancer	56
Abstract LB-A006: Impact of pharmacokinetic profiles on the in vivo antitumor efficacy of EHMT2 inhibitors combined with immune checkpoint blockade	55
Abstract LB-C011: Using Organoids and Tumor Infiltrating Lymphocytes to Elucidate the ”Dark Matter” of Human Tumor Antigens	55
Abstract A046: Dendritic cell dysfunction predicts adverse prognosis in high-risk acute lymphoblastic leukemia	54
Different PD-L1 Assays Reveal Distinct Immunobiology and Clinical Outcomes in Urothelial Cancer	54
Abstract A028: Combination therapy with a TCR Vβ-directed bifunctional molecule, cisplatin and anti-PD-1 promotes antitumor activity in immune checkpoint blockade-refractory head and neck murine tumor	52
Abstract A041: LAG-3 is associated with poor prognosis and LAG-3 blockade enhances the efficacy of PD-1 blockade combined with radiation therapy in breast cancer	52
Abstract C070: Targeting neoantigens conserved across organs and species overcomes tumor immune escape	49
Single-Cell Analysis of Posttranslational Modifications Identifies Immunosuppressive Macrophage Subtypes in the HBV-Positive Hepatocellular Carcinoma Microenvironment	48
Abstract B035: Antibody-lectin chimeras for glyco-immune checkpoint blockade	48
Optimal Neoantigen Cancer Vaccines Target CD8+ and CD4+ T Cells with Multiple Antigens	46
Reciprocal Interactions Between the Gut Microbiome and Mammary Tissue Mast Cells Promote Metastatic Dissemination of HR+ Breast Tumors	46
IL-15 Complex Enhances Agonistic Anti-CD40 + Anti-PDL1 by Correcting the T-bet to Tox Ratio in CD8+ T cells Infiltrating Pancreatic Ductal Adenocarcinoma	45
Combination Therapy Approaches to Enhance the Efficacy of ERV-Targeting Vaccines in Cancer	45

Transforming the Dark into Light: A Siglec-9 Switch	44
CLN-617 Retains IL2 and IL12 in Injected Tumors to Drive Robust and Systemic Immune-Mediated Antitumor Activity	44
The ω-3 Polyunsaturated Fatty Acid Docosahexaenoic Acid Enhances NK-Cell Antitumor Effector Functions	43
A Population of TIM4+FOLR2+ Macrophages Localized in Tertiary Lymphoid Structures Correlates to an Active Immune Infiltrate Across Several Cancer Types	43
Preclinical Characterization and Phase I Study of an Anti–HER2-TLR7 Immune-Stimulator Antibody Conjugate in Patients with HER2+ Malignancies	40
IL18 at the Crossroads between Chronic Inflammation and T-cell Exhaustion in Pancreatic Cancer	39
Topical resiquimod elicits systemic protection and improves anti-PD1 therapy in melanoma via priming of CD8+ T cells	38
T-cell Senescence in the Tumor Microenvironment	37
Engineering CD20 CARs with a Twist	36
A Sampling of Highlights from the Literature	36
Profiling Multiple CD8+ T-cell Functional Dimensions Enhances Breast Cancer Immune Assessment	35
A Sampling of Highlights from the Literature	35
Harnessing Microbiota to Improve Immunotherapy for Gastrointestinal Cancers	35
Circulating Neoantigen- and Viral Oncoprotein–Specific CD8+ T Cells Share a Transcriptional Signature	35
Identification and Phenotypic Characterization of Neoantigen-Specific Cytotoxic CD4+ T Cells in Endometrial Cancer	34
Ethnicity, Immunity, and Outcomes: Biology versus Socioeconomic Status	33
A Universal Boosting Strategy for Adoptive T-cell Therapy Using a Paired Vaccine/Chimeric Antigen Receptor	33
Cannabidiol Enhances Atezolizumab Efficacy by Upregulating PD-L1 Expression via the cGAS–STING Pathway in Triple-Negative Breast Cancer Cells	32
Antibody-Mediated Inhibition of HLA/LILR Interactions Breaks Innate Immune Tolerance and Induces Antitumor Immunity	32
Abstract LB-B005: No effect of the time-of-day infusion of adjuvant pembrolizumab in the outcomes of patients with resectable melanoma in the NCI/SWOG trial S1404	31
Abstract B024: The clinical benefit from treatment of advanced MSS mCRC with the adenosine 2a/2b antagonist etrumadenant is associated with adenosine-mediated T-cell exclusion and enhancement of the e	31
Abstract LB-B013: Eight-Pathway transcriptomic biomarker outperforms PD-L1 for anti-PD-1 response prediction in melanoma	31
Abstract A062: Endometriosis as a Neuroimmune Disorder: Integrating Inflammation, Innervation, and Sensitization	30
Abstract C032: Comparison of genomic drivers and transcriptomic features of immunogenicity in pancreatic malignancies	30
Abstract B058: Longitudinal single cell and TCRβ profiling of a melanoma patient during adjuvant immune checkpoint inhibitor therapy exhibits significant change in immune cell profiles	30
Abstract A042: Onco-fetal immune tolerance factors shape T cell exhaustion and immune evasion in pregnancy and cancer	30
Abstract A075: Molecular glues activate immunoproteasomes to amplify and expand the MHC-class-I immunopeptidome that promotes TCR-engineered T-cell cytotoxic activity against multiple myeloma	29
Abstract A061: First-in-human hapten-enhanced stressed-ghost cell immunotherapy (STC-1010) for advanced colorectal cancer: preclinical and early clinical data	29
Abstract B005: Harnessing GD2-CAR macrophages to target high-risk neuroblastoma	29
Abstract A074: Immune dysregulation and B-cell fitness driven by PLCγ2 R665W: Insights from a novel conditional B-cell mouse model	28
Abstract A031: Systemic Inflammatory Biomarkers and Lu-177-PSMA Radiopharmaceutical Therapy Response in Sipuleucel-T-Pretreated Metastatic Castration-Resistant Prostate Cancer	28
Abstract C066: Matrix-M adjuvant – A promising adjuvant for preventative and therapeutic cancer vaccines development	28
High Expression of MHC Class I Overcomes Cancer Immunotherapy Resistance Due to IFNγ Signaling Pathway Defects	28
Ncoa2 Promotes CD8+ T cell–Mediated Antitumor Immunity by Stimulating T-cell Activation via Upregulation of PGC-1α Critical for Mitochondrial Function	27
Low TCR Binding Strength Results in Increased Progenitor-like CD8+ Tumor-Infiltrating Lymphocytes	27
Abstract B074: Killing cancer cells by suicidal bombing attack with neutrophil extracellular traps	27
The HSP90 Inhibitor Pimitespib Targets Regulatory T Cells in the Tumor Microenvironment	27
In situ vaccination, low-dose targeted radionuclide therapy, and immune checkpoint inhibition eradicate poorly immunogenic metastatic tumors in murine cancer models	26
Evaluation of Proton Minibeam Radiotherapy on Antitumor Immune Responses in a Rat Model of Glioblastoma	26
Cancer Cell–Intrinsic SSBP4 Enables Tumor Immune Evasion by Promoting Cholesterol Biosynthesis	26
SPP1+ Tumor-Associated Macrophages Drive Immunotherapy Resistance via CD8+ T-cell Dysfunction in Clear-Cell Renal Cell Carcinoma	26
CLK1 Promotes Myeloid-Derived Suppressor Cell Trafficking and Reprograms the Tumor Microenvironment by Activating Hippo/YAP Signaling in Colorectal Cancer	26
Loss of miR-29a/b1 Cluster Reprograms the Tumor Microenvironment and Contributes to Immunosuppression in Lung Cancer	26
The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission	26
Age-Associated Contraction of Tumor-Specific T Cells Impairs Antitumor Immunity	26
FOXM1-Specific TCR-Engineered T Cells Target Non–Small Cell Lung Cancer	26
Abstract C021: Cryo-Immune Vaccination (CIV): A locoregional device/multidrug immunotherapeutic approach that can bypass toxicity yet systemically eradicate metastatic cancers	25
Spatial Organization of Macrophages in CTL-Rich Hepatocellular Carcinoma Influences CTL Antitumor Activity	25
Abstract C062: Tryptophan degradation by intestinal Bacteroides induces anti-tumor immunity and limits melanoma growth	25
Abstract B018: Sphingomyelin-derived nanovesicles for the delivery of the IDO1 inhibitor epacadostat enhance metastatic and post-surgical melanoma immunotherapy	25

About the Rising Star	25
Abstract A045: Overcoming platelet-mediated immune suppression in ovarian cancer	25
PIKfyve Inhibition Induces Antitumor Immunogenicity by Attenuating STING Trafficking and Lysosomal Degradation	25
A Sampling of Highlights from the Literature	25
Abstract A012: Cancer acquires therapy resistance by converting immune infiltration to exclusion through NK cell-macrophage interactions	24
CCRL2 Expression by Specialized Lung Capillary Endothelial Cells Controls NK-cell Homing in Lung Cancer	23
Acknowledgment to Reviewers	23
Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma	23
Denosumab Enhances Antitumor Immunity by Suppressing SPP1 and Boosting Cytotoxic T Cells	22
In Vivo Labeling Resolves Distinct Temporal, Spatial, and Functional Properties of Tumor Macrophages and Identifies Subset-Specific Effects of PD-L1 Blockade	22
TCR-Based Therapy Directed against Kallikrein-Related Peptidase 4 Is Safe and Effective against Prostate Cancer	22
Tumor-Associated CD19+CD39− B Regulatory Cells Deregulate Class-Switch Recombination to Suppress Antibody Responses	22
Improvement of Tumor Neoantigen Detection by High-Field Asymmetric Waveform Ion Mobility Mass Spectrometry	22
Pseudomonas aeruginosa Exacerbates Bladder Cancer Progression by Activating Cancer-Driven Immunosuppression	21
A Sampling of Highlights from the Literature	21
ATF7ip Inhibits the Tumor Immune Response by Promoting Terminal CD8+ T-cell Exhaustion	21
Setdb1 Loss Induces Type I Interferons and Immune Clearance of Melanoma	21
Automated Computational Flow Cytometry Correlates Decreasing Neutrophil-to-Lymphocyte Ratio to Improved Survival in NSCLC after Immune Checkpoint Blockade	21
Abstract PR-05: Sumoylation blockade exposes the dark epigenome to drive ZBP1 viral mimicry for cancer immunotherapy	20
Targeting LxCxE Cleft Pocket of Retinoblastoma Protein in Immunosuppressive Macrophages Inhibits Ovarian Cancer Progression	20
Abstract A040: Measurement of CD8+ T cell-mediated anti-tumor immune response induced by neoadjuvant chemo-radiation therapy using T-cell receptor analysis in rectal cancer patient	20
Systematic Engineering of TROP2-Targeted CAR T-Cell Therapy Overcomes Resistance Pathways in Solid Tumors	19
The E3 Ubiquitin Ligase FBXO38 Maintains the Antitumor Function of Natural Killer Cells by Sustaining IL15R Signaling	19
Abstract LB-A008: Reversing immune checkpoint inhibitor resistance rherapy in advanced thyroid cancer	19
Reprogramming CD8+ T-cell Branched N- Glycosylation Limits Exhaustion, Enhancing Cytotoxicity and Tumor Killing	19
Determinants for Antitumor and Protumor Effects of Programmed Cell Death	19
Abstract LB-C004: Epigenetic immune reprogramming overcomes PD-1 resistance in metastatic melanoma patients: the phase II NIBIT-ML1 study	19
Battle Within the Sexes: Differences in Male and Female Immunity and the Impact on Antitumor Responses	19
Autoantibodies Drive Heart Damage Caused by Concomitant Radiation and PD-1 Blockade	19
Abstract C046: High-throughput phenotypic screening reveals novel immunomodulators that enhance immunotherapy in high-risk neuroblastoma	19
Coexisting Alterations of MHC Class I Antigen Presentation and IFNγ Signaling Mediate Acquired Resistance of Melanoma to Post–PD-1 Immunotherapy	18
CXCL10 Recruitment of γδ T Cells into the Hypoxic Bone Marrow Environment Leads to IL17 Expression and Multiple Myeloma Progression	18
Increased CaMKK2 Expression Is an Adaptive Response That Maintains the Fitness of Tumor-Infiltrating Natural Killer Cells	18
Atypical B Cells Promote Cancer Progression and Poor Response to Bacillus Calmette-Guérin in Non–Muscle Invasive Bladder Cancer	18
Neutralizing Antibodies Impair the Oncolytic Efficacy of Reovirus but Permit Effective Combination with T cell–Based Immunotherapies	18
Translating Science into Survival: Report on the Seventh International Cancer Immunotherapy Conference	18
IGM-7354, an Immunocytokine with IL15 Fused to an Anti–PD-L1 IgM, Induces NK and CD8+ T cell–Mediated Cytotoxicity of PD-L1–Positive Tumor Cells	18
Intratumoral TREX1 Induction Promotes Immune Evasion by Limiting Type I IFN	18
IL1R2 Deficiency Unleashes Neutrophil-Mediated Antitumor Potential in Sarcoma	18
A Sampling of Highlights from the Literature	17
Abstract B003: Oncolytic VSVd51-LIGHT and folfirinox chemotherapy increases anti-tumor immune response in pancreatic ductal adenocarcinoma	17
Abstract A043: Single-cell and bulk transcriptomics uncovers GATA3-mediated macrophage immunosuppressive programming in murine and human cancers	17
CD8+ T Cells Keep Their (K+)urrency for Function	17
Abstract B070: Fc-optimized GITR antibody enhances a CD4 T cell-dendritic cell crosstalk to promote anti-tumor immunity	17
A Sampling of Highlights from the Literature: Article Recommendations from Our Deputy and Senior Editors	17
A Sampling of Highlights from the Literature	17
Single-Cell Clonal Lineage Tracing Identifies the Transcriptional Program Controlling the Cell-Fate Decisions by Neoantigen-Specific CD8+ T Cells	17
Abstract A011: IL-12 armored anti-macrophage CAR T cells reset and reprogram the tumor microenvironment to control metastatic ovarian and lung tumor growth	17
Abstract B011: Mast cells mediate tumor-suppressive effects in head and neck cancer through immune-microenvironmental regulation	17
Abstract LB-B006: A Phase II chemo/immunotherapy study using metronomic gemcitabine, doxorubicin, docetaxel and nivolumab for advanced angiosarcoma (NCT04535713): An interim analysis	16
Antitumor Immune Responses in B2M -Deficient Cancers	16
Constitutive STAT3 Signaling, in Comparison with STAT5, Enhances CAR T-cell Efficacy and Lowers Systemic Toxicity	16
MerTK Induces Dysfunctional Dendritic Cells by Metabolic Reprogramming	16
CAR Binders Affect CAR T-cell Tonic Signaling, Durability, and Sensitivity to Target	16
Abstract LB-A002: Open-label, Phase Ib dose-expansion study assessing the efficacy of the CD137/FAP agonist BI 765179 plus pembrolizumab as first-line therapy in metastatic or incurable, recurrent PD-	16
Combination CXCR4 and PD-1 Blockade Enhances Intratumoral Dendritic Cell Activation and Immune Responses Against Hepatocellular Carcinoma	16
Pan-Cancer Single-Cell RNA Sequencing Analysis Refines Multi-Origin Monocyte and Macrophage Lineages	16
Cancer Immunology Research: A Decade of Illumination and Innovation	15
A Sampling of Highlights from the Literature: Article Recommendations from Our Deputy and Senior Editors	15
A Sampling of Highlights from the Literature: Article Recommendations from Our Deputy and Senior Editors	15
Tim-3 Sustains Tumor Treg Stability and Function, Limiting Checkpoint Blockade Therapy Efficacy	15
Tumor-Derived Complement C3 Overexpression in STK11 -Mutant Lung Adenocarcinoma Drives Tumor Growth and Immune Checkpoint Inhibitor Resistance	15
A Sampling of Highlights from the Literature	15
A Metabolic Axis of Immune Intractability	15
Inhibitor of Apoptosis Proteins Antagonist Induces T-cell Proliferation after Cross-Presentation by Dendritic Cells	15
Regulatory Considerations for Genome-Edited T-cell Therapies	15
The PO4-tential for Less Toxic CAR T-cell Therapies	15
M9657 Is a Bispecific Tumor-Targeted Anti-CD137 Agonist That Induces MSLN-Dependent Antitumor Immunity without Liver Inflammation	14
Identification of Core Techniques That Enhance Genome Editing of Human T Cells Expressing Synthetic Antigen Receptors	14
Abstract IA03: Therapeutic modulation of nucleic acids-induced immune activation	14
Targeting SALL4 with an HLA Class I–Restricted TCR for Cancer Immunotherapy	14
The Immunopeptidome from a Genomic Perspective: Establishing the Noncanonical Landscape of MHC Class I–Associated Peptides	14
Abstract C020: Spatial and molecular landscape in clear cell renal cell carcinoma bone metastatic patients	14
Abstract B022: Investigating Biased GPCRs Activation by Nutraceutical Caffeine and Nicotine in Transactivating Glycosylated Receptors to Induce EMT in Cancer Metastasis	14
A “Function-First” Approach to Identify Regulatory T cell–Targeting Antibodies for Immunotherapy	14
CD206+CD14− Skin-Resident Macrophages and DC–T Cell Clusters Are Spatial Features Characterizing Nonrelapsing Cutaneous Squamous Cell Carcinoma	14
Abstract A005: Utility of an oncogene-driven spontaneous triple-negative breast cancer model for immunotherapeutic testing	14
Immunogenetic Metabolomics Reveals Key Enzymes That Modulate CAR T-cell Metabolism and Function	13
Abstract A065: Fast and cost-effective prediction of treatment response in head and neck cancer by characterizing the tumor microenvironment from routine H&E slides	13
Abstract C057: Tankyrase Inhibition Reprograms Melanoma Metastases to Overcome Resistance to PD-1 Blockade	13

Nanobody-Directed CEA-Targeting CAR T Cells Eliminate Gastrointestinal Cancer Xenografts	13
Transient EZH2 Suppression by Tazemetostat during In Vitro Expansion Maintains T-Cell Stemness and Improves Adoptive T-Cell Therapy	13
Abstract B064: Association of different TP53 mutation subtypes with the efficacy of first-line immunotherapy in locally advanced and metastatic lung squamous cell carcinoma	13
Immunotherapy Inhibits Tumor Cholesterol Synthesis via the IFNγ–IRF1–SREBF2 Axis	13
The Effects of Clinically Relevant Radionuclides on the Activation of an IFN1 Response Correlate with Radionuclide Half-life and Linear Energy Transfer and Influence Radiopharmaceutical Antitumor Effi	13
TLR5 Signaling Causes Dendritic Cell Dysfunction and Orchestrates Failure of Immune Checkpoint Therapy against Ovarian Cancer	13
Abstract A066: MMR-stratified spatial programs of normal and cancer-associated fibroblasts and their association with lymphocyte pervasiveness in CRC	13
Abstract B002: A LIBRARY OF POTENT TCRS DERIVED FROM HEALTHY DONORS TARGETING KRAS G12D AND G12V NEOANTIGENS	13
Abstract C005: Understanding the Role of Tonic TCR Signaling to Optimize CAR-T Efficacy	13
Abstract B007: Tissue-Specific B Cell Differentiation Limits Anti-Tumor Efficacy of Radiation and Immunotherapy	12
Abstract LB-C010: Flare: A clinical stage platform designed to overcome challenges of the tumor microenvironment and universally target tumors of epithelial origin	12
HER2Δ16 Engages ENPP1 to Promote an Immune-Cold Microenvironment in Breast Cancer	12
Immune Modulation of Innate and Adaptive Responses Restores Immune Surveillance and Establishes Antitumor Immunologic Memory	12
A Sampling of Highlights from the Literature: Article Recommendations from Our Deputy and Senior Editors	12
CD4+ Regulatory T Cells in Human Cancer: Subsets, Origin, and Molecular Regulation	12
Abstract IA04: Reprogramming the tumor–immune microenvironment: From stromal circuits to engineered microbial immunotherapies	12
Abstract LB-C006: Scalable TCR synthesis and screening enable antigen reactivity mapping	12
Abstract B075: Innate lymphoid cell reprogramming reveals immunometabolic and epigenetic signatures following checkpoint blockade in head and neck squamous cell carcinoma (HNSCC)	12
ATOR-4066, a Bispecific Antibody Targeting CD40 and CEACAM5, Induces Strong Myeloid and T Cell–Dependent Tumor Immunity and Synergizes with PD-1 Blockade	12
Abstract A049: CD8+ T cell decline from regression to recurrence in ovarian cancer is linked to expansion of suppressive macrophages	12
The CCL17–CCR4 Axis Is Critical for Mutant STAT6-Mediated Microenvironmental Remodeling and Therapeutic Resistance in Relapsed/Refractory Diffuse Large B-Cell Lymphoma	12
Antigen Priming Induces Functional Reprogramming in iNKT Cells via Metabolic and Epigenetic Regulation: An Insight into iNKT Cell-Based Antitumor Immunotherapy	12
Allogeneic CAR T Cells: Complex Cellular Therapy Designs Test the Limits of Our Preclinical Models	12
Abstract A051: Integrative Single-Cell and Spatial Transcriptomics Reveal Metabolic Reprogramming and Spatiotemporal Transition of Macrophages Driving Immune Suppression in Head and Neck Cancer	12
Dual Chimeric Antigen Receptor T Cells Targeting CD38 and SLAMF7 with Independent Signaling Demonstrate Preclinical Efficacy and Safety in Multiple Myeloma	12
CD73 Inhibits cGAS–STING and Cooperates with CD39 to Promote Pancreatic Cancer	11
TIME for Endometrial Cancer: Advancements and Challenges in Therapeutic Targets for the Endometrial Cancer Tumor Immune Microenvironment	11
PI3K/Akt Signaling Pathway Regulates CD155 Expression Involved in Resistance to Cancer Immunotherapy	11
Long-Read Sequencing Reveals Alternative Splicing-Driven, Shared Immunogenic Neoepitopes Regardless of SF3B1 Status in Uveal Melanoma	11
Combination of Anti–PD-1 and Electroacupuncture Induces a Potent Antitumor Immune Response in Microsatellite-Stable Colorectal Cancer	11
Distinct Spatially Resolved Tumor Microenvironment Trajectories Define Benefit from Ramucirumab plus Pembrolizumab in Refractory PD-L1+ Gastric Cancer	11
Small Gene Networks Delineate Immune Cell States and Characterize Immunotherapy Response in Melanoma	11
CD49a Targeting Enhances NK Cell Function and Antitumor Immunity	11
Sequential Exposure to IL21 and IL15 During Human Natural Killer Cell Expansion Optimizes Yield and Function	11
Cytometric Atlas of Combination Immunotherapy in Pancreatic Cancer: Blood-Based Signatures Reveal Vaccine and Checkpoint Inhibitor Responses	11
Impact of scFv on Functionality and Safety of Third-Generation CD123 CAR T Cells	11
The Conventional Dendritic Cell 1 Subset Primes CD8+ T Cells and Traffics Tumor Antigen to Drive Antitumor Immunity in the Brain	11
Low Serum Apolipoprotein A1 Levels Impair Antitumor Immunity of CD8+ T Cells via the HIF-1α–Glycolysis Pathway	11
Engineering CD3/CD137 Dual Specificity into a DLL3-Targeted T-Cell Engager Enhances T-Cell Infiltration and Efficacy against Small-Cell Lung Cancer	11
Upregulation of an Epithelial miRNA Is Associated with Immune Evasion in Progressive Bronchial Premalignant Lesions	11
Unlocking the Immune Response in ALK-Rearranged Lung Adenocarcinoma	10
Abstract A015: The emerging role of basophils in non-muscle-invasive bladder cancer	10
Let the Guard Down: cAMP Activators Can Improve Immunotherapy in GBM	10
Abstract A004: A minimal gene panel approach for cost-effective identification of tumor-reactive T cells	10
About the Rising Star	10
A Sampling of Highlights from the Literature: Article Recommendations from Our Deputy and Senior Editors	10
Abstract IA04: Investigating T cell immunobiology using genetically engineered models	10
Efficacy and Synergy with Cisplatin of an Adenovirus Vectored Therapeutic E1E2E6E7 Vaccine against HPV Genome–Positive C3 Cancers in Mice	10
Abstract A005: TAZ-TEAD signaling alters the immune microenvironment of cutaneous melanoma	10
Abstract B025: Anti-GD2 combined with anti-PD1 enhances tumor immunity with T cell memory via inducing immunogenic cell death	10
Abstract C051: Genomic and spatial immune biomarkers predictive of chemoimmunotherapy response in triple-negative breast cancer	10
Abstract C023: Tertiary lymphoid structures generate anti-tumor immunity independently of immune responses in secondary lymphoid organs upon STING and lymphotoxin-β receptor activation	10
Abstract LB-B012: Signals from the tumor immune microenvironment induce a potent immune modulatory gene expression program in senescent breast tumor cells	9
Abstract C044: Analysis of 1000 secreted proteins in functional genomics and compound screens reveals cytotoxic and immunomodulatory targets	9
Abstract A006: Assessment of EBV DNA methylation to guide antiviral use in EBV-associated lymphoma	9
Chronic ISG15 Exposure Accelerates CD8+ T-cell Dysfunction while Increasing PD-1 Blockade Sensitivity in Oral Squamous Cell Carcinoma	9
Systemic Alterations in Type-2 Conventional Dendritic Cells Lead to Impaired Tumor Immunity in Pancreatic Cancer	9
Abstract IA08: Development and use of Engineered Regulatory T cells to treat Autoimmune Diseases	9
A Sampling of Highlights from the Literature	9
Mesenchymal Stem Cells and Fibroblasts Contribute to Microvascular Proliferation in Glioblastoma and are Correlated with Immunosuppression and Poor Outcome	9
Tyrosine Kinase Inhibition Activates Intratumoral γδ T Cells in Gastrointestinal Stromal Tumor	9
Abstract C008: NFIL3 emerges as a driver of CAR T cell dysfunction from integrated in vivo/in vitro CRISPR screen	9
Interactions between MDSCs and the Autonomic Nervous System: Opportunities and Challenges in Cancer Neuroscience	9
Abstract A023: Myeloid checkpoint blockade potentiates radiotherapy by modulating dendritic cells and reducing Treg-driven immunosuppression	9
The TRIB2–DNMT1 Pathway Generates an Immune-Cold Microenvironment in Glioblastoma, and Its Inhibition Promotes Immunotherapy	9
The Dark Knight: Functional Reprogramming of Neutrophils in the Pathogenesis of Colitis-Associated Cancer	9
TBK1 Targeting Is Identified as a Therapeutic Strategy to Enhance CAR T-Cell Efficacy Using Patient-Derived Organotypic Tumor Spheroids	9
High-Dimensional Analyses Reveal IL15 Enhances Activation of Sipuleucel-T Lymphocyte Subsets and Reverses Immunoresistance	9
Host Tissue Factors Predict Immune Surveillance and Therapeutic Outcomes in Gastric Cancer	9
iBRIDGE: A Data Integration Method to Identify Inflamed Tumors from Single-cell RNA-Seq Data and Differentiate Cell Type–Specific Markers of Immune-Cell Infiltration	9
Abstract A072: The T cell precursor frequency determines the immunogenicity of cancer neoantigens	9
Abstract B036: Systemic and tumor-microenvironment inflammation shape outcomes in patients with immunologically cold, treatment-refractory tumors treated with Fc-enhanced anti–CTLA-4 botensilimab	9
Abstract A017: Neutrophil extracellular traps reprogram macrophages to an immunosuppressive phenotype in non-small-cell lung cancer	9
A Sampling of Highlights from the Literature	9
The Problem with Syngeneic Mouse Tumor Models	9
Tertiary Lymphoid Structures Are Associated with Enhanced Macrophage Activation and Immune Checkpoint Expression and Predict Outcome in Cervical Cancer	9
Abstract B027: iSIGN panel identifies germ cell tumors via whole-proteome phage immunoprecipitation sequencing	9
Abstract PR-15: Neuroimmune dysregulation in ovarian cancer: the role of chronic stress on microglial activation and systemic inflammation	9
A Sampling of Highlights from the Literature: Article Recommendations from Our Deputy and Senior Editors	9